Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The IFN-I response could expose tumor cells to surveillance by the immune system.
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
DNA demethylating agents can induce a type I IFN response in cancer cells through de-repression of endogenous retroviruses and activation of the MDA5-MAVS pathway.
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could augment tumor immunogenicity.
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Inactivated typical enhancers in HCC are associated with collagen fibril organization and chemotaxis GO terms and enriched for binding motifs of immune-related TFs, including STAT1.
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The Results section on DNMT inhibitors and type I interferon signaling reports STAT1 upregulation in ovarian cancer cell lines, but does not analyze inactivated enhancers in HCC. Searches for collagen fibril organization, chemotaxis, and enhancer-binding motifs found no passage addressing the claimed associations. (LLM, conf=0.75)
Experimental — accuracy not yet measuredInhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages.
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
DNMT inhibitors are consistently linked to derepression of endogenous retroviral elements and strong type I and type III interferon signaling.
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
This dual epigenetic targeting may influence additional antiproliferative mechanisms and enhance antitumor immune surveillance.
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,719 · see citing works
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,610 · see citing works
Self-citationCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,480 · see citing works
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,311 · see citing works
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works
Self-citationA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · see citing works
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works
Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis
Mi, S., Lee, X., Li, X., Veldman, G. M., Finnerty, H. F., Collins‐Racie, L. A., LaVallie, E. R., Tang, X.-Y., Edouard, P., Howes, S., et al. (2000) · Nature · doi:10.1038/35001608 · Cited by 1,660 · see citing works
Lentivirus-delivered stable gene silencing by RNAi in primary cells.
Stewart, S. A., Dykxhoorn, D. M., Palliser, D., Mizuno, H., Yu, E. Y., An, D., Sabatini, D., Chen, I. S. Y., Hahn, W., Sharp, P., et al. (2003) · RNA: A publication of the RNA Society · doi:10.1261/rna.2192803 · Cited by 1,619 · see citing works
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,426 · see citing works
Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., Finch, C. E., St. Laurent III, G., Kenny, P. J., & Wahlestedt, C. (2008) · Nature Medicine · doi:10.1038/nm1784 · Cited by 1,416 · see citing works
COBRA: a sensitive and quantitative DNA methylation assay
Xiong, Z., & Laird, P. W. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.12.2532 · Cited by 1,188 · see citing works
Transcription of IAP endogenous retroviruses is constrained by cytosine methylation
Walsh, C. P., Chaillet, J. R., & Bestor, T. H. (1998) · Nature Genetics · doi:10.1038/2413 · Cited by 1,105 · see citing works
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · see citing works
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711 · see citing works
Self-citationMechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E. M., & Pardoll, D. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 690 · see citing works
Self-citationJuergens, R. A., Wrangle, J. M., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686 · see citing works
Self-citationBerger, R., Rotem‐Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren‐Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680 · see citing works
Tsai, H.-C., Li, H., Neste, L. V., Cai, Y., Robert, C., Rassool, F. V., Shin, J., Harbom, K., Beaty, R. M., Pappou, E. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 651 · see citing works
Self-citationIntrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells
Grow, E. J., Flynn, R. A., Chavez, S. L., Bayless, N. L., Wossidlo, M., Wesche, D. J., Martin, L., Ware, C. B., Blish, C. A., Chang, H. Y., et al. (2015) · Nature · doi:10.1038/nature14308 · Cited by 647 · see citing works
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88
Tarallo, V., Hirano, Y., Gelfand, B. D., Dridi, S., Kerur, N., Kim, Y., Cho, W. G., Kaneko, H., Fowler, B. J., Bogdanovich, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.036 · Cited by 592 · see citing works
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M. S., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 574 · see citing works
O’Hagan, H. M., Wang, W., Sen, S., Shields, C. E. D., Lee, S. S., Zhang, Y. W., Clements, E. G., Cai, Y., Neste, L. V., Easwaran, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.012 · Cited by 569 · see citing works
Self-citationRetroelements and the human genome: New perspectives on an old relation
Bannert, N., & Kurth, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404838101 · Cited by 517 · see citing works
Lambda Interferon Inhibits Hepatitis B and C Virus Replication
Robek, M. D., Boyd, B. S., & Chisari, F. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3851-3854.2005 · Cited by 432 · see citing works
Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R. J., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 428 · see citing works
Self-citationApproval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Kaminskas, E., Farrell, A. M., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S., Leighton, J. K., Patel, H. R., Rahman, A., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2135 · Cited by 424 · see citing works
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia
Egan, M. F., Straub, R. E., Goldberg, T. E., Yakub, I., Callicott, J. H., Hariri, A. R., Mattay, V. S., Bertolino, A., Hyde, T. M., Weickert, C. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405077101 · Cited by 416 · see citing works
Ultraviolet radiation damages self noncoding RNA and is detected by TLR3
Bernard, J. J., Cowing-Zitron, C., Nakatsuji, T., Muehleisen, B., Muto, J., Borkowski, A. W., Martinez, L., Greidinger, E. L., Yu, B., & Gallo, R. L. (2012) · Nature Medicine · doi:10.1038/nm.2861 · Cited by 408 · see citing works
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390 · see citing works
Alterations of immune response of non-small cell lung cancer with Azacytidine
Wrangle, J. M., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F. P., Criekinge, W. V., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 385 · see citing works
Self-citationFunctional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines
Stresemann, C., Brueckner, B., Musch, T., Stopper, H., & Lyko, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2821 · Cited by 385 · see citing works
Blond, J.-L., Besème, F., Duret, L., Bouton, O., Bedin, F., Perron, H., Mandrand, B., & Mallet, F. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.1175-1185.1999 · Cited by 377 · see citing works
Cytosolic RNA:DNA hybrids activate the cGAS–STING axis
Mankan, A. K., Schmidt, T., Chauhan, D., Goldeck, M., Höning, K., Gaidt, M. M., Kubarenko, A. V., Andreeva, L., Hopfner, K., & Hornung, V. (2014) · The EMBO Journal · doi:10.15252/embj.201488726 · Cited by 359 · see citing works
Insertional polymorphisms of full-length endogenous retroviruses in humans
Turner, G., Barbulescu, M., Su, M., Jensen-Seaman, M. I., Kidd, K. K., & Lenz, J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00455-9 · Cited by 358 · see citing works
Tristem, M. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3715-3730.2000 · Cited by 330 · cited 4× · see citing works
“Aza-Induced Human Endogenous Retrovirus Transcripts Can Activate Viral Defense Responses in EOC The above data suggests Aza might activate endogenous retroviral sequences (ERVs) that constitute more than 8% of the human genome, can activate cytosolic RNA sensors, and are silenced in normal somatic cells by promoter DN…”
InfluentialOver 20% of human transcripts might form sense-antisense pairs
Chen, J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh818 · Cited by 323 · see citing works
Creation of genomic methylation patterns
Bestor, T. H., & Tycko, B. (1996) · Nature Genetics · doi:10.1038/ng0496-363 · Cited by 310 · see citing works
Leonova, K. I., Brodsky, L., Lipchick, B. C., Pal, M., Novototskaya, L. R., Chenchik, A. A., Sen, G. C., Komarova, E. A., & Gudkov, A. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216922110 · Cited by 260 · see citing works
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 248 · see citing works
de Parseval, N., Lazar, V., Casella, J., Benit, L., & Heidmann, T. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10414-10422.2003 · Cited by 237 · see citing works
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer
Wang‐Johanning, F., Liu, J., Rycaj, K., Huang, M. L., Tsai, K. L., Rosen, D. G., Chen, D., Lu, D. W., Barnhart, K. F., & Johanning, G. L. (2006) · International Journal of Cancer · doi:10.1002/ijc.22256 · Cited by 225 · see citing works
Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines
Schaefer, M., Hagemann, S., Hanna, K., & Lyko, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0458 · Cited by 219 · see citing works
HERV-H RNA is abundant in human embryonic stem cells and a precise marker for pluripotency
Santoni, F. A., Guerra, J., & Luban, J. (2012) · Retrovirology · doi:10.1186/1742-4690-9-111 · Cited by 215 · see citing works
Demystified . . . Human endogenous retroviruses
Nelson, P. N., Carnegie, P., Martin, J., Ejtehadi, H. D., Hooley, P., Roden, D., Rowland-Jones, S., Warren, P., Astley, J., & Murray, P. G. (2003) · Molecular Pathology · doi:10.1136/mp.56.1.11 · Cited by 210 · see citing works
Karpf, A. R., Peterson, P. W., Rawlins, J. T., Dalley, B. K., Yang, Q., Albertsen, H., & Jones, D. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14007 · Cited by 194 · see citing works
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Odunsi, K. O., Matsuzaki, J., James, S. R., Mhawech-Fauceglia, P. Y., Tsuji, T., Miller, A., Zhang, W., Akers, S. N., Griffiths, E. A., Miliotto, A. J., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0126 · Cited by 193 · see citing works
Quantitation of HERV-K env gene expression and splicing in human breast cancer
Wang-Johanning, F., Frost, A., Jian, B., Epp, L., Lu, D. W., & Johanning, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206241 · Cited by 191 · see citing works
Wang‐Johanning, F., Rycaj, K., Plummer, J. B., Li, M., Yin, B., Frerich, K., Garza, J. G., Shen, J., Lin, K., Yan, P., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr540 · Cited by 177 · see citing works
Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.
Wang‐Johanning, F., Frost, A. R., Johanning, G. L., Khazaeli, M. B., LoBuglio, A. F., Shaw, D. R., & Strong, T. V. (2001) · PubMed · Cited by 174 · see citing works
Strick, R., Ackermann, S., Langbein, M., Swiatek, J., Schubert, S. W., Hashemolhosseini, S., Koscheck, T., Fasching, P. A., Schild, R. L., Beckmann, M. W., et al. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0104-y · Cited by 173 · see citing works
Self-citationMaksakova, I. A., Mager, D. L., & Reiss, D. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8494-3 · Cited by 172 · see citing works
Karpf, A. R., Lasek, A. W., Ririe, T. O., Hanks, A. N., Grossman, D., & Jones, D. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.18 · Cited by 148 · see citing works
Epigenetic silencing of multiple interferon pathway genes after cellular immortalization
Kulaeva, O. I., Drăghici, S., Tang, L., Kraniak, J. M., Land, S. J., & Tainsky, M. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206594 · Cited by 142 · see citing works
Activation of the innate immune response by endogenous retroviruses
Hurst, T. P., & Magiorkinis, G. (2014) · Journal of General Virology · doi:10.1099/jgv.0.000017 · Cited by 139 · see citing works
Blaise‐Boisseau, S., de Parseval, N., & Heidmann, T. (2005) · Retrovirology · doi:10.1186/1742-4690-2-19 · Cited by 120 · see citing works
Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Krishnamurthy, J., Rabinovich, B. A., Mi, T., Switzer, K. C., Olivares, S., Maiti, S. N., Plummer, J. B., Singh, H., Kumaresan, P. R., Huls, H. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3197 · Cited by 120 · see citing works
Karpf, A. R., Bai, S., James, S. R., Mohler, J. L., & Wilson, E. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0400 · Cited by 115 · see citing works
CpG methylation suppresses transcriptional activity of human syncytin-1 in non-placental tissues
Matoušková, M., Blažková, J., Pajer, P., Pavlı́ček, A., & Hejnar, J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.12.010 · Cited by 112 · see citing works
Gimenez, J., Montgiraud, C., Pichon, J.-P., Bonnaud, B., Arsac, M., Ruel, K., Bouton, O., & Mallet, F. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp1214 · Cited by 111 · see citing works
Regulation of human endogenous retrovirus‐K expression in melanomas by CpG methylation
Stengel, S., Fiebig, U., Kurth, R., & Denner, J. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20751 · Cited by 107 · see citing works
Rycaj, K., Plummer, J. B., Yin, B., Li, M., Garza, J. G., Radvanyi, L. G., Ramondetta, L. M., Lin, K., Johanning, G. L., Tang, D. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0388 · Cited by 106 · see citing works
Ruebner, M., Strissel, P. L., Ekici, A. B., Stiegler, E., Dammer, U., Goecke, T. W., Faschingbauer, F., Fahlbusch, F. B., Beckmann, M. W., & Strick, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056145 · Cited by 97 · see citing works
Self-citationThe role of human endogenous retroviruses in trophoblast differentiation and placental development
Rote, N. S., Chakrabarti, S., & Stetzer, B. P. (2004) · Placenta · doi:10.1016/j.placenta.2004.02.008 · Cited by 96 · see citing works
Self-citationCancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma
Guan, J., Gupta, R., & Filipp, F. V. (2015) · Scientific Reports · doi:10.1038/srep07857 · Cited by 92 · see citing works
Strissel, P. L., Ruebner, M., Thiel, F. C., Wachter, D. L., Ekici, A. B., Wolf, F., Thieme, F., Ruprecht, K., Beckmann, M. W., & Strick, R. (2012) · Oncotarget · doi:10.18632/oncotarget.679 · Cited by 88 · see citing works
Self-citationIssa, J. J. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0355 · Cited by 87 · see citing works
Activation of the innate immune response by endogenous retroviruses
Hurst, T. P., & Magiorkinis, G. (2015) · Journal of General Virology · doi:10.1099/vir.0.000017 · Cited by 82 · see citing works
Löwer, R., Löwer, J., Tondera, C., & Kurth, R. (1993) · Virology · doi:10.1006/viro.1993.1066 · Cited by 76 · see citing works
Bidirectional regulation between WDR83 and its natural antisense transcript DHPS in gastric cancer
Su, W., Li, J.-T., Cui, Y., Hong, J., Du, W., Wang, Y.-C., Lin, Y., Xiong, H., Wang, J., Kong, X., et al. (2012) · Cell Research · doi:10.1038/cr.2012.57 · Cited by 73 · see citing works
Syncytin immunoreactivity in colorectal cancer: Potential prognostic impact
Larsen, J. M., Christensen, I. J., Nielsen, H. J., Hansen, U., Bjerregaard, B., Talts, J. F., & Larsson, L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.008 · Cited by 65 · see citing works
Okada, M., Ogasawara, H., Kaneko, H., Hishikawa, T., Sekigawa, I., Hashimoto, H., Maruyama, N., Kaneko, Y., & Yamamoto, N. (2002) · PubMed · Cited by 64 · see citing works
Ding, S., Khoury-Hanold, W., Iwasaki, A., & Robek, M. D. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001758 · Cited by 56 · see citing works
Bénit, L., Calteau, A., & Heidmann, T. (2003) · Virology · doi:10.1016/s0042-6822(03)00163-6 · Cited by 55 · see citing works
DNA methylation and nucleosome occupancy regulate the cancer germline antigen geneMAGEA11
James, S. R., Cedeno, C. D., Sharma, A. K., Zhang, W., Mohler, J. L., Odunsi, K. O., Wilson, E. M., & Karpf, A. R. (2013) · Epigenetics · doi:10.4161/epi.25500 · Cited by 54 · see citing works
Henke, C., Strissel, P. L., Schubert, M.-T., Mitchell, M., Stolt, C. C., Faschingbauer, F., Beckmann, M. W., & Strick, R. (2015) · Retrovirology · doi:10.1186/s12977-015-0138-8 · Cited by 42 · see citing works
Self-citationIdentification of endogenous retroviral reading frames in the human genome
Villesen, P., Aagaard, L., Wiuf, C., & Pedersen, F. (2004) · Retrovirology · doi:10.1186/1742-4690-1-32 · Cited by 37 · see citing works
Peroxisomal MAVS activates IRF1-mediated IFN-λ production
Ding, S., & Robek, M. D. (2014) · Nature Immunology · doi:10.1038/ni.2924 · Cited by 30 · see citing works
(Some) Cellular Mechanisms Influencing the Transcription of Human Endogenous Retrovirus, HERV-Fc1
Laska, M. J., Nissen, K. K., & Nexø, B. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053895 · Cited by 23 · see citing works
Reduced DICER1 Elicits an Interferon Response in Endometrial Cancer Cells
Chiappinelli, K. B., Haynes, B. C., Brent, M. R., & Goodfellow, P. J. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0520 · Cited by 21 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works
The molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809 · see citing works
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works
Self-citationTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · see citing works
Self-citationThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · see citing works
Self-citationThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · see citing works
RIG-I-like receptors: their regulation and roles in RNA sensing
Rehwinkel, J., & Gack, M. U. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0288-3 · Cited by 1,703 · see citing works
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672 · see citing works
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · see citing works
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · see citing works
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,528 · see citing works
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,491 · see citing works
Ten things you should know about transposable elements
Bourque, G., Burns, K. H., Gehring, M., Gorbunova, V., Seluanov, A., Hammell, M., Imbeault, M., Izsvák, Z., Levin, H. L., Macfarlan, T. S., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1577-z · Cited by 1,430 · see citing works
Regulatory activities of transposable elements: from conflicts to benefits
Chuong, E. B., Elde, N. C., & Feschotte, C. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.139 · Cited by 1,343 · see citing works
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · see citing works
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J. J., & Baylin, S. B. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,132 · see citing works
Self-citationCold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau‐Guilemond, J., Valsesia‐Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,102 · see citing works
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077 · see citing works
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y., Borad, M. J., Sachdev, J. C., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J., Kim, T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 994 · see citing works
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P. J., Cameron, S. B., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C. A., Petruzzelli, L., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.17 · Cited by 948 · see citing works
Beg, M. S., Brenner, A. J., Sachdev, J. C., Borad, M. J., Kang, Y., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 910 · see citing works
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 876 · see citing works
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G. A. M., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 792 · see citing works
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.052 · Cited by 693 · see citing works
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J., et al. (2019) · Nature · doi:10.1038/s41586-018-0768-9 · Cited by 697 · see citing works
The cGAS–STING pathway and cancer
Samson, N., & Ablasser, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00468-w · Cited by 705 · see citing works
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 656 · see citing works
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 653 · see citing works
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 595 · see citing works
Self-citationCancer stemness, intratumoral heterogeneity, and immune response across cancers
Miranda, A., Hamilton, P. T., Zhang, A. W., Pattnaik, S., Becht, É., Mezheyeuski, A., Bruun, J., Micke, P., de Reyniès, A., & Nelson, B. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818210116 · Cited by 580 · see citing works
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 574 · see citing works
Transposable elements in cancer
Burns, K. H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.35 · Cited by 572 · see citing works
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & Carvalho, D. D. D. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550 · see citing works
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works
Glioma epigenetics: From subclassification to novel treatment options
Gusyatiner, O., & Hegi, M. E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.010 · Cited by 547 · see citing works
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537 · see citing works
Self-citationDNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung, H., Kim, H. S., Kim, J. Y., Sun, J., Ahn, J. S., Ahn, M., Park, K., Esteller, M., Lee, S., & Choi, J. K. (2019) · Nature Communications · doi:10.1038/s41467-019-12159-9 · Cited by 537 · see citing works
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 519 · see citing works
Self-citationRegulation of transposable elements by DNA modifications
Deniz, Ö., Frost, J. M., & Branco, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0106-6 · Cited by 480 · see citing works
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468 · see citing works
The role of retrotransposable elements in ageing and age-associated diseases
Gorbunova, V., Seluanov, A., Mita, P., McKerrow, W., Fenyö, D., Boeke, J. D., Linker, S. B., Gage, F. H., Kreiling, J. A., Petrashen, A. P., et al. (2021) · Nature · doi:10.1038/s41586-021-03542-y · Cited by 457 · see citing works
Integrated Molecular Characterization of Testicular Germ Cell Tumors
Shen, H., Shih, J., Hollern, D. P., Wang, L., Bowlby, R., Tickoo, S. K., Thórsson, V., Mungall, A. J. J., Newton, Y., Hegde, A. M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.039 · Cited by 457 · see citing works
Nabet, B. Y., Qiu, Y., Shabason, J. E., Wu, T. J., Yoon, T., Kim, B. C., Benci, J. L., DeMichele, A. M., Tchou, J. C., Marcotrigiano, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.031 · Cited by 453 · see citing works
Roles of transposable elements in the regulation of mammalian transcription
Fueyo, R., Judd, J., Feschotte, C., & Wysocka, J. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00457-y · Cited by 451 · see citing works
Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation
Ahmad, S., Mu, X., Yang, F., Greenwald, E., Park, J. W., Jacob, E., Zhang, C.-Z., & Hur, S. (2018) · Cell · doi:10.1016/j.cell.2017.12.016 · Cited by 449 · see citing works
Cellular origins of dsRNA, their recognition and consequences
Chen, Y. G., & Hur, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00430-1 · Cited by 430 · see citing works
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Moroishi, T., Hayashi, T., Pan, W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A., & Guan, K. (2016) · Cell · doi:10.1016/j.cell.2016.11.005 · Cited by 435 · see citing works
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433 · see citing works
Self-citationRegulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors
Onomoto, K., Onoguchi, K., & Yoneyama, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00602-7 · Cited by 427 · see citing works
Interferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 423 · see citing works
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 418 · see citing works
Double-Stranded RNA Sensors and Modulators in Innate Immunity
Hur, S. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041356 · Cited by 420 · see citing works
Immune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 398 · see citing works
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W. T., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 404 · see citing works
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I. S., Cohen, I., Maeda, M., Shindo, M., Şenbabaoğlu, Y., Watson, M. J., Leftin, A., Maniyar, R. R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 394 · see citing works
Self-citationResurrection of endogenous retroviruses during aging reinforces senescence
Liu, X., Liu, Z., Wu, Z., Ren, J., Fan, Y., Sun, L., Cao, G., Niu, Y., Zhang, B., Ji, Q., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.017 · Cited by 390 · see citing works
Measuring and interpreting transposable element expression
Lanciano, S., & Cristofari, G. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0251-y · Cited by 390 · see citing works
DNA damage and repair in age-related inflammation
Zhao, Y., Simon, M. A., Seluanov, A., & Gorbunova, V. A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00751-y · Cited by 393 · see citing works
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377 · see citing works
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369 · see citing works
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 364 · see citing works
Self-citationTransposable elements in human genetic disease
Payer, L. M., & Burns, K. H. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0165-8 · Cited by 344 · see citing works
Alternative tumour-specific antigens
Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 353 · see citing works
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
Liu, H., Golji, J., Brodeur, L. K., Chung, F. S., Chen, J. T., deBeaumont, R. S., Bullock, C., Jones, M. D., Kerr, G., Li, L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0302-5 · Cited by 346 · see citing works
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Cao, J., & Yan, Q. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 298 · see citing works
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348 · see citing works
Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D. G. F., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L. R., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 347 · see citing works
Human Endogenous Retroviruses Are Ancient Acquired Elements Still Shaping Innate Immune Responses
Grandi, N., & Tramontano, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02039 · Cited by 342 · see citing works
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 345 · see citing works
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
Brocks, D., Schmidt, C. R., Daskalakis, M., Jang, H. S., Shah, N. M., Li, D., Li, J., Zhang, B., Hou, Y., Laudato, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3889 · Cited by 339 · see citing works
Regulation of cGAS- and RLR-mediated immunity to nucleic acids
Ablasser, A., & Hur, S. (2019) · Nature Immunology · doi:10.1038/s41590-019-0556-1 · Cited by 333 · see citing works
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 336 · see citing works
Epigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 331 · see citing works
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 325 · see citing works
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 318 · see citing works
Self-citationEnnishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318 · see citing works
A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation
Dias, A. G., Sampaio, N. G., & Rehwinkel, J. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.08.007 · Cited by 309 · see citing works
Gut stem cell necroptosis by genome instability triggers bowel inflammation
Wang, R., Li, H., Wu, J., Cai, Z., Li, B., Ni, H., Qiu, X., Chen, H., Liu, W., Yang, Z., et al. (2020) · Nature · doi:10.1038/s41586-020-2127-x · Cited by 310 · see citing works
Self-citationTumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 316 · see citing works
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 310 · see citing works
Self-citationEndogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121476 · Cited by 303 · see citing works
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J., Pasero, P., & Postel-Vinay, S. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 300 · see citing works
Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency
Mehdipour, P., Marhon, S. A., Ettayebi, I., Chakravarthy, A., Hosseini, A., Wang, Y., de Castro, F. A., Yau, H. L., Ishak, C. A., Abelson, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2844-1 · Cited by 298 · see citing works
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 297 · see citing works
Parikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y.-L., Raabe, M. J., Thel, H. L., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 298 · see citing works
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M. K., Shih, I., Wang, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 293 · see citing works
Self-citationPappalardi, M. B., Keenan, K., Cockerill, M. J., Kellner, W. A., Stowell, A. I. J., Sherk, C. S., Wong, K., Pathuri, S., Briand, J., Steidel, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00249-x · Cited by 293 · see citing works
Self-citationMarked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285 · see citing works
Kong, Y., Rose, C. M., Cass, A. A., Williams, A. G., Darwish, M., Lianoglou, S., Haverty, P. M., Tong, A.-J., Blanchette, C., Albert, M. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13035-2 · Cited by 285 · see citing works
Guler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277 · see citing works
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275 · see citing works
Self-citationKDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Zhang, S.-M., Cai, W. L., Liu, X., Thakral, D., Luo, J., Chan, L. H., McGeary, M. K., Song, E., Blenman, K. R. M., Micevic, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03994-2 · Cited by 272 · see citing works
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 272 · see citing works
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 267 · see citing works
Immune responses to endogenous retroelements: taking the bad with the good
Kassiotis, G., & Stoye, J. P. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.27 · Cited by 261 · see citing works
DNA methylation in mammalian development and disease
Smith, Z. D., Hetzel, S., & Meissner, A. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00760-8 · Cited by 280 · see citing works
Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00185-w · Cited by 254 · see citing works
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
Hu, M., Zhou, M., Bao, X., Pan, D., Jiao, M., Liu, X., Li, F., & Li, C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139333 · Cited by 244 · see citing works
Lysine catabolism reprograms tumour immunity through histone crotonylation
Yuan, H., Wu, X., Wu, Q., Chatoff, A. G., Megill, E., Gao, J., Huang, T., Duan, T., Yang, K., Jin, C., et al. (2023) · Nature · doi:10.1038/s41586-023-06061-0 · Cited by 241 · see citing works
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
